Christine Caul-Futy

This study evaluates the tolerance and innate immune response of human respiratory epithelial cells to FLAMOD, a flagellin-based therapy, showing dose-dependent activation of immune pathways without tissue damage.

This study shows flagellin activates TLR5 in human airway epithelium, enhancing immune responses in both healthy and diseased states, but not directly reducing bacterial load.